Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Non-homologous end-joining factor 1 (NHEJ1), also known as XLF or Cernunnos, is a DNA repair protein essential for the non-homologous end joining (NHEJ) pathway, which mediates the repair of DNA double-strand breaks (DSBs)[1][2][5]. NHEJ1 is required for the ligation steps that rejoin DNA ends and is also involved in critical processes such as V(D)J recombination, necessary for immune diversity[1][2][5]. The protein interacts with key repair factors, including XRCC4 and DNA ligase IV, forming complexes that bridge and stabilize DNA ends prior to ligation[1][2][5]. Dysfunction or mutation in NHEJ1 results in severe combined immunodeficiency, developmental defects, and increased sensitivity to DNA-damaging agents, underlining its essential role in genome integrity and immune system function[1][2][4][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Non-homologous end-joining factor 1 (NHEJ1).